Oxford Biomedica cuts 2026 guidance despite record client wins

Oxford Biomedica's half-year update contains two competing messages. Commercial demand appears healthy, but converting that demand into near-term revenue is taking longer than expected.

The cell and gene therapy specialist now expects 2026 revenue of £180 million to £200 million. Its reported EBITDA margin is forecast to be in the low-single digits, reflecting client delays, changes in ordering behaviour and the slower ramp-up of a US facility.

Against that, Oxford Biomedica PLC signed a record 17 new clients during the first half. Its potential new business pipeline also grew by around 30% year-on-year to approximately $713 million.

For investors, the central question is whether 2026 represents a temporary timing problem or a warning that future contracts will take longer to translate into profitable revenue.

Oxford Biomedica's key half-year figures

Measure	H1 2026 update
Revenue	Approximately £80 million
Revenue growth	Around 9%
New clients signed	17
Revenue backlog	Approximately £193 million
Contracted client orders	Approximately £97 million
Potential new business pipeline	Approximately $713 million
Gross cash at 30 June 2026	£75 million
Net cash at 30 June 2026	£21 million
Updated 2026 revenue guidance	£180 million to £200 million

The full figures will arrive with Oxford Biomedica's interim results on 22 September 2026. The original company announcement provides the definitions behind its backlog, orders and pipeline measures.

Revenue is growing, but the year remains second-half weighted

Revenue for the six months ended 30 June 2026 increased by around 9% to approximately £80 million. Management said this reflected its previously communicated expectation that more revenue would fall into the second half.

Oxford Biomedica has approximately £165 million of forecast 2026 revenue covered by contracted client orders, although recognition remains subject to revenue performance obligations. These are the contractual conditions that must be satisfied before revenue can be recorded.

That coverage provides useful visibility, but it does not remove execution risk. The company still needs projects to progress on schedule and clients to approve and order the relevant work packages.

This distinction matters because Oxford Biomedica is reporting strong demand while simultaneously lowering near-term expectations. The problem is not presented as a shortage of potential work. It is the timing and phasing of that work.

Why 2026 guidance has been lowered

Oxford Biomedica now expects full-year revenue of £180 million to £200 million. The previous revenue guidance was not restated in this announcement, so the precise size of the reduction is not disclosed.

Management identified three main pressures.

First, selected programmes have been deferred or delayed because of changes in client strategy or clinical data. Development-stage therapies can move unpredictably, particularly when trial results affect a client's investment decisions.

Second, a larger client changed its procurement strategy and approval pathway. The financial impact associated with this client was not separately disclosed.

Third, operational readiness at Oxford Biomedica's Durham, North Carolina site was later than expected after a six-month delay to the integration plan. Management says the site is now back on track, with its first good manufacturing practice, or GMP, run taking place. GMP refers to the regulated standards governing pharmaceutical production.

Some clients are also taking a staged approach to ordering work packages. That means Oxford Biomedica may secure a relationship without immediately receiving an order for the contract's full potential value.

Profitability is still improving, just more slowly

The company expects an EBITDA margin in the mid-single digits before one-off costs and the low-single digits on a reported basis.

EBITDA is earnings before interest, tax, depreciation and amortisation. It is commonly used to assess underlying operating performance, although it does not include every cash and accounting cost.

Lower revenue means Oxford Biomedica has fewer sales over which to spread its operating cost base. This is sometimes described as weaker cost absorption. For a manufacturing business with specialist facilities and skilled staff, short-term revenue delays can therefore have a noticeable effect on margins.

Even so, the company expects continued progress in profitability during 2026 rather than a return to an EBITDA loss. That is a positive, although the gap between the reported low-single-digit margin and the longer-term ambition approaching 30% remains substantial.

Record client wins support the longer-term case

Oxford Biomedica signed 17 new clients in the first half, more than 30% above the total number signed during the whole of 2025. This was described as record new client activity.

Its non-risk-adjusted new business pipeline increased by around 30% year-on-year to approximately $713 million. Non-risk-adjusted means the figure represents the potential gross value of opportunities before allowing for the probability that individual projects may not proceed.

The company also reported a revenue backlog of approximately £193 million and contracted client orders worth around £97 million. The two figures should not be treated as interchangeable. Backlog represents ordered CDMO revenue available to earn, while contracted orders represent signed financial commitments from clients.

Management says the client portfolio is becoming more mature and diversified, with an increasing number of late-stage and commercial-stage programmes. The previously announced commercial supply agreement with Bristol Myers Squibb, covering lentiviral vectors for its CAR-T portfolio, is presented as further evidence of Oxford Biomedica's commercial-scale capabilities.

CDMO stands for contract development and manufacturing organisation. Oxford Biomedica develops and manufactures viral vectors for pharmaceutical and biotechnology clients rather than relying solely on therapies of its own.

Cash has reduced during the first half

Gross cash stood at £75 million on 30 June 2026, compared with £97 million at the end of 2025. Net cash declined from £55 million to £21 million over the same period.

The announcement says this position supports continued investment in growth and operational execution, but it does not provide a full first-half cash flow statement. Investors will need to wait until September to assess the drivers behind the reduction, including investment, working capital and one-off spending.

Cash conversion will be important as Oxford Biomedica expands its operations while operating at relatively modest near-term margins.

Ambitions for 2027 and 2030 remain unchanged

Despite lowering its near-term expectations, Oxford Biomedica has retained its medium and long-term ambitions.

It continues to guide for revenue growth of 25% to 30% in 2027, alongside an EBITDA margin of at least 10%. Management also plans to explore additional profitability measures.

The company still aims to generate approximately £500 million of revenue in 2030. As revenue scales, management expects operational leverage and cost discipline to support a long-term EBITDA margin approaching 30%.

These targets imply a sharp improvement from the performance expected in 2026. They are ambitions rather than guarantees, and their credibility will depend on timely project progression, successful client conversion and reliable execution across Oxford Biomedica's manufacturing network.

What investors should watch on 22 September

The interim results need to provide more detail on the revised revenue range, cash movement and Durham site ramp-up. Investors should also look for evidence that staged client orders are turning into larger committed work packages.

Record client acquisition, a growing pipeline and broader late-stage exposure all support the long-term story. The weaker 2026 outlook, falling net cash and sensitivity of margins to delayed revenue provide the counterweight.

Oxford Biomedica's commercial engine appears to be generating opportunities. The next test is whether management can convert them into revenue and cash quickly enough to deliver the unchanged 2027 ambitions.